Table 3 Neonatal and maternal secondary outcomes
Characteristics | IPDMA | Van Vliet | Salim | ||||||
|---|---|---|---|---|---|---|---|---|---|
Maternal outcomes | Nifedipine (n = 321) | Atosiban (n = 321) | HR or OR (95% CI) or χ2 test | Nifedipine (n = 246) | Atosiban (n = 251) | HR (95% CI) or χ2 test | Nifedipine (n = 75) | Atosiban (n = 70) | HR (95% CI) or χ2 test |
GA at delivery (weeks)a | 33 + 6 (31 + 1–37 + 2) | 33 + 0 (30 + 3–36 + 3) | HR 0.80 (0.67–0.95), p = 0.013 | 33 + 1 (30 + 4–37 + 0) | 32 + 3 (30 + 1–36 + 0) | HR 0.85 (0.70–1.03), p = 0.10 | 36 + 4 (34 + 0–38 + 1) | 34 + 5 (33 + 0–38 + 0) | HR 0.60 (0.40–0.90), p = 0.014 |
Time to delivery (days)a | 18 (2–44) | 10 (2–42) | HR 0.83 (0.69–0.99), p = 0.038 | 7.5 (1.0–39.0) | 4.0 (1.0–38.5) | HR 0.88 (0.72–1.06), p = 0.18 | 35.0 (23.0–49.5) | 32.0 (15.0–50.0) | HR 0.61 (0.40–0.94), p = 0.024 |
Successful 48 hours of tocolysis | 247 (77) | 243 (76) | OR 1.06 (0.73–1.53), p = 0.77 | 177 (72) | 181 (72) | OR 0.99 (0.67–1.47) | 70 (93) | 62 (89) | OR 1.81 (0.56–5.81) |
Neonatal outcomes | Nifedipine (n = 392) | Atosiban (n = 380) | OR or MD (95% CI) | Nifedipine (n = 294) | Atosiban (n = 289) | OR or MD (95% CI) | Nifedipine (n = 98) | Atosiban (n = 91) | OR or MD (95% CI) |
NICU admission | 182 (46) | 225 (59) | 0.32 (0.14–0.75), p = 0.008 | 153 (52) | 179 (62) | 0.53 (0.29–0.96), p = 0.037 | 29 (30) | 46 (51) | 0.32 (0.018–5.71), p = 0.44 |
Ventilation support | |||||||||
 - CPAP | – | – | – | 111/251 (44) | 131/252 (52) | 0.69 (0.44–1.07), p = 0.098 | – | – | 0 |
 - Intubation | 52/355 (15) | 66/349 (19) | 0.65 (0.13–3.38), p = 0.61 | 42/257 (16) | 53/258 (21) | 0.68 (0.098–4.73), p = 0.70 | 10 (10) | 13 (14) | 0.56 (0.033–9.71), p = 0.69 |
Birthweight | 2077 (1604–2717) | 1985 (1532–2568) | 112 (−85–309), p = 0.26 | 1983 (1503–2674) | 1845 (1435–2465) | 139 (−59–336), p = 0.16 | 2351 (1985–2894) | 2243 (1930–2761) | 251 (−47–550), p = 0.097 |